Ignite Creation Date:
2024-05-06 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 12:51 PM
Study NCT ID:
NCT03631407
Status:
COMPLETED
Last Update Posted:
2022-07-12
First Post:
2018-08-09
Brief Title:
Safety and Efficacy of Vicriviroc MK-7690 in Combination With Pembrolizumab MK-3475 in Participants With AdvancedMetastatic Microsatellite Stable MSS Colorectal Cancer CRC MK-7690-046
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-09-24
Start Date Type:
ACTUAL
Primary Completion Date:
2021-06-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-06-08
Completion Date Type:
ACTUAL
First Submit Date:
2018-08-09
First Submit QC Date:
August 13 2018
Study First Post Date:
2018-08-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2022-06-07
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-06-21
Last Update Post Date:
2022-07-12
Last Update Post Date Type:
ACTUAL